

Transparency
Declaration for
Payments by Chugai
Pharma Europe and
Chugai Pharma UK in
the UK & Ireland in
2016, 2017 & 2018

Healthcare Compliance
Chugai Pharma Europe Ltd

Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. believe it is critical to be transparent regarding our interactions with Healthcare Professionals (HCPs), Other Relevant Decision Makers (ORDMs), Health Care Organisations (HCOs), national healthcare services (including the NHS) and with Patient Organisations. Chugai upholds the key elements of all engagements which are clarity of purpose, integrity, independence and transparency. The company recognises the interests of a Patient Organisation and a pharmaceutical company are distinct but will overlap. Chugai considers Patient Organisations can provide its members with key insight, intelligence and support. It can ensure Chugai develop medicines that have the best potential of adding value to the lives of people (patients and carers) by better understanding what is needed.

Patients benefit from the collaboration between HCPs/ORDMs and the pharmaceutical industry through the development and appropriate use of innovative treatments that aim to improve patient care. HCPs/ORDMs and pharmaceutical companies regularly work together from early scientific research and clinical trial programmes to the use of medicines. As an integral part of the medicines development process it is entirely appropriate that fees are paid to HCPs/ORDMs to reimburse them for their time and expertise.

Payments made to HCPs/ORDMs and HCOs will be disclosed via central portals organised and managed by The Irish Pharmaceutical Healthcare Association (IPHA) and The Association of the British Pharmaceutical Industry (ABPI) for payments made in Ireland the UK respectively. These payments will be available for public scrutiny from the end of June for payments made the previous year and updated annually. Details for payments are available for three years and Chugai retains the information for a minimum of five years. Methodological notes will give support any to reader to better understand the manner in which Chugai manages such payments.

Chugai Pharma UK Ltd. and Chugai Pharma Europe Ltd. will occasionally work with a Patient Organisation and payments made will be disclosed via the company website. Details will be given as to the Patient Organisation, the nature of the engagement, the amount paid and a percentage this payment represents of the annual income of the patient organisation and updated annually and made available for the previous three years. If the payment was for consultancy work undertaken by an HCP, working on behalf of a Patient Organisation, then the payment will be disclosed twice (on the Chugai website as a payment to a Patient Organisation and on the ABPI or IPHA transparency portals as a payment to an HCP. Each Patient Organisation, with whom Chugai Pharma UK has worked with, is encouraged to disclose all payments in the most transparent manner.

The NHS and the pharmaceutical industry share a common goal in improving patient outcomes and this has been the foundation of Joint Working projects. The potential of such projects to deliver improvements that benefit patients has been proven in a range of services and therapies. Payments relating to Joint Working agreements will be disclosed via the company website and details will be given as to the NHS partner, the nature of the engagement and the amount paid. Such information is disclosed prior to the project starting and updated through the course of the project.

Here you can find information regarding: (click on the link below or scroll)

[Payments made in 2018](#)

[Payments made in 2017](#)

[Payments made in 2016](#)

[Methodological notes explaining the process how Chugai manages disclosure](#)

The amounts indicated represents payments made in the UK and Ireland for each calendar year. The data has been sourced from all Chugai businesses. The amounts indicated excludes money spent by our partners where we co-promote products. The amounts shown are exclusive of VAT and taxes where this is applicable.

Roche Products Limited and Chugai Pharma U.K. Ltd. have in place a co-promotion agreement for a Prescription Only Medicine (POM). To ensure both companies adhere with the ABPI requirements, each company will independently disclose payments associated with this co-promotion. Chugai Pharma U.K. Ltd. have distribution agreements with business partners based outside the UK. These business partners are responsible for the disclosure of any payments made by them.

For further information, please contact disclosure@chugai-pharm.co.uk.

Payments made in 2018

Interactions with Patient Organisations:

Listed on this page you will find all financial interactions that Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. has had with Patient Organisations during 2018. This includes financial donations to help with the service provided to patients, carers and family members. Chugai has made every effort to ensure the accuracy of this data.

Name of the Patient Organisation	Nature of interaction	Value of support
The Haemophilia Society	<p>A grant to support specific project costs associated with the Haemophilia Society annual general meeting and conference 17-18th Nov. 2018. Further details available on request.</p> <p>The total funding given to this group represents less than 1% of its total earnings in 2018</p> <p>The Haemophilia Society is a registered charity No. 288260 in England & Wales, No. SCO39732 in Scotland</p> <p>https://haemophilia.org.uk/</p>	£5,000
The Haemophilia Society	<p>A grant to support The Haemophilia Society to enhance its website to be able to provide more information on national and local events. Chugai had no input with regards to content or design. Further details available on request.</p> <p>The total funding given to this group represents less than 4% of its total earnings in 2018</p> <p>The Haemophilia Society is a registered charity No. 288260 in England & Wales, No. SCO39732 in Scotland</p> <p>https://haemophilia.org.uk/</p>	£20,000
NMO-Spectrum-UK	<p>A grant to support the Green & Golden Summer Ball on 1st Sept 2018 organised by NMO-UK. Chugai had no input with regards content of the event or attended. Further details available on request.</p> <p>The Patient Organisation has not provided Chugai with detail of total income, so the company is unable to inform what the donation to this group represents as a total of its earnings in 2018.</p> <p>NMO-Spectrum-UK is a registered charity No. 1158104</p>	£750

	https://www.nmouk.org/	
NMO-Spectrum-UK	<p>A grant to support the NMO-Spectrum newsletter and media campaign on raising awareness of NMO. Further details available on request.</p> <p>The Patient Organisation has not provided Chugai with detail of total income, so the company is unable to inform what the donation to this group represents as a total of its earnings in 2018</p> <p>NMO-Spectrum-UK is a registered charity No. 1158104</p> <p>https://www.nmouk.org/</p>	£1000
Total		£26 750

Joint Working:

Joint Working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery.

Chugai Pharma U.K. Ltd. will comply with Joint Working policies as defined by the ABPI and IPHA Codes of Practice in all discussions and arrangements.

Name of Joint Working Project	No joint working agreements were discussed or undertaken in 2018
--------------------------------------	--

Payments made in 2017

Interactions with Patient Organisations:

Listed on this page you will find all financial interactions that Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. has had with Patient Organisations during 2017. This includes financial donations to help with the service provided to patients, carers and family members. Chugai has made every effort to ensure the accuracy of this data.

Name of the Patient Organisation	Nature of interaction	Value of support
Myeloma UK	<p>Donation following reactive request of a donation of £10,000 to support core activities undertaken by Myeloma UK including patient and family information and support, Healthcare professional programmes, policy and public affairs</p> <p>The total funding given to this group represents less than 2% of its total earnings in 2017</p> <p>Myeloma UK Charity No. SC 026116</p> <p>https://www.myeloma.org.uk/</p>	£10,000
Myeloma UK	<p>For a member of staff to attend an advisory board meeting (not a registered Healthcare Professional)</p> <p>The total funding given to this group represents less than 1% of its total earnings in 2017</p> <p>Myeloma UK Charity No. SC 026116</p> <p>https://www.myeloma.org.uk/</p>	£800
Total		£10 800

Joint Working:

Joint Working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery.

Chugai Pharma U.K. Ltd. will comply with Joint Working policies as defined by the ABPI and IPHA Codes of Practice in all discussions and arrangements.

Name of Joint Working Project	No joint working agreements were discussed or undertaken in 2017
--------------------------------------	--

Payments Made in 2016

1. Interactions with Patient Organisations:

Listed on this page you will find all financial interactions that Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. has had with Patient Organisations during 2016. This includes financial donations to help with the service provided to patients, carers and family members. Chugai has made every effort to ensure the accuracy of this data.

Name of the Patient Organisation	Nature of interaction	Value of support
Roy Castle Lung Cancer Foundation	<p>The Medical Director for The Roy Castle Foundation attended an advisory board arranged by Chugai Pharma UK to discuss the patient impact of lung cancer in the UK.</p> <p>For more information, go to https://www.roycastle.org/.</p> <p>This funding represents c. 0.2% of total income for the organisation.</p> <p>Registered Charity England & Wales 1046854 - Scotland SC037596</p>	£1012.50
NMO UK Rare Illness Research Foundation CIC	<p>Grant provided by Chugai Pharma Europe Ltd to be used towards activities performed by NMO UK to raise awareness of a clinical study to NMO-UK members, HCPs and the community at large.</p> <p>For more information, go to http://nmo-ukresearchfoundation.org/</p> <p>The total funding given to this group represents less than 2% of its total earnings in 2016</p> <p>NMO UK charity No. 1158104)</p>	£1000
NMO UK Rare Illness Research Foundation CIC	<p>Donation provided by Chugai Pharma Europe Ltd towards activities performed by NMO UK to host an event in relation to supporting individual sufferers of NMO Spectrum Disorders.</p> <p>For more information, go to http://nmo-ukresearchfoundation.org/</p> <p>The total funding given to this group represents less than 2% of its total earnings in 2016</p>	£600

	NMO UK charity No. 1158104)	
Total		£2 612.50

2. Joint Working:

Joint Working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery.

Chugai Pharma U.K. Ltd. will comply with Joint Working policies as defined by the ABPI Code of Practice in all discussions and arrangements.

Name of Joint Working Project	No joint working agreements were discussed or undertaken in 2016
--------------------------------------	--



Methodological Notes on Disclosure

CHUGAI PHARMA EUROPE & UK LTD

CONTENTS

Introduction	11
Definitions:	12
How we manager Transfers of Value	19
How we manage consent	19
How we manage Research and Development	20
Tax and VAT considerations	21
Links to Codes.....	21
Contacts	21

Introduction

Chugai frequently collaborates with health experts with a view to developing pragmatic solutions that will help patients across the UK and Ireland access highly innovative medicines and address the current challenges facing the healthcare sector.

Chugai has robust processes for engaging with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) which are subject to internal scrutiny by the appropriate functions. All engagements are planned in accordance with The Association of British Pharmaceutical Industry (ABPI) and Irish Pharmaceutical Healthcare Association (IPHA) Codes of Practice.

The ABPI and IPHA Codes of Practice require Chugai to disclose specific transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs). In addition, and where required, such transfers of value (including direct payments) should be disclosed at a named individual level.

This requires companies to document and publicly disclose transfers of value made directly or indirectly to HCPs and HCOs. Each company providing transfers of value must publish a note summarising the methodology used in preparation of the disclosure and identifying each category of transfer of value (ToV).

Chugai is committed to ensuring that the relationship between the industry and HCPs, Other Relevant Decision Makers (ORDMs) and HCOs is better understood. Chugai welcomes this increased transparency and believes it is in the best interests of the pharmaceutical industry, the Irish and British healthcare section and ultimately patients. Chugai takes the principles of disclosure seriously and understands the balance between disclosure and privacy rights and will always respect both important elements.

This document outlines the methodology and definitions used by Chugai in relation to such disclosure. For further information please go to <https://www.abpi.org.uk/ethics/ethical-responsibility/disclosure-uk/>.

Definitions:

Term	Definition
Methodological Notes	<p>These notes provide detail how Chugai manages disclosure and individual consent to disclose as companies manage these in different ways dependent upon the nature of the payments and business setup. The objective is to provide a narrative to allow the reader to understand that we take disclosure and consent seriously and strive to make the information as clear as possible and provide the information in the most accessible manner. Chugai welcomes any feedback to help improve these notes and the overall information provided (please contact disclosure@chugai-pharm.co.uk).</p>
Transfer(s) of Value (ToV):	<p>The term ‘transfer of value’ means a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of the recipient. An indirect transfer of value is one made by a third party on behalf of a company for the benefit of a recipient where the third party’s identity is known to, or can be identified by, the recipient. An indirect transfer of value could also be the cost of travel or accommodation incurred by the company for the HCP to complete work where the HCP has been contracted by the company (e.g. attending an advisory board meeting).</p> <p>Chugai (including Chugai Pharma Europe (CPE) and Chugai Pharma UK (CPU)) will disclose all ToV to HCPs and HCOs in accordance with its commitment to these Codes on Disclosure of all appropriate Transfers of Value.</p> <p>These payments will be disclosed via country-specific central repositories which will allow the reader to access all payments made by members of the pharmaceutical industry. Payments made to patient organisations will be disclosed separately on the Chugai Pharma UK website (https://www.chugai-pharm.co.uk/).</p>
Healthcare Organisation (HCO):	<p>Chugai regards HCOs as hospitals, universities, private medical groups and other places of work for HCPs treating patients or providing associated advice or management services related to the treatment of patients. In addition, all medical societies (national or local) and all “networks” of associations for HCPs are regarded as HCOs.</p> <p>Private companies such as medical education agencies, or suppliers of “temp” nurses, etc. are not typically regarded as HCOs, especially where most employees are non-HCPs.</p>

Healthcare Professional (HCP)	<p>For the purposes of disclosure, Chugai regards all employees of a Health Care Provider as HCPs regardless of their professional status. In addition, Chugai regards all registered or qualified HCPs as within the scope of disclosure regardless of their status. Thus, retired HCPs fall within scope and academic staff who provide clinical services and support.</p> <p>Where HCPs are employed directly and exclusively by Chugai their salary and benefits are outside the scope of disclosure. Part-time employees will fall within the scope of disclosure for all payments made by the company, including salary.</p> <p>Note that HCPs have the right to opt out from individual disclosure (Refer to Data Privacy and Consent section).</p>
Language and Local Requirements	<p>The ABPI and IPHA Codes require disclosure to be available in the country where the HCP is registered to practice and presented in a manner which best allows the reader the opportunity to understand the nature of the relationship between the company, HCP/HCO and ToV. This includes the information being presented in a local language. Some Member States have developed central repositories where the public can access all ToV in one place. Chugai supports this practice and where data is being disclosed will provide financial support to manage this development. Where a Member State has adopted a legal framework relating to disclosure then the local Codes of Practice and legal requirements are strictly adhered to with the most stringent being a benchmark for general guidance.</p>
Fair Market Value	<p>Chugai usually compensate HCPs for their time when working with the company. The decision to not be paid is one made by the HCP. The payment rate is determined by a process known as Fair Market Value (FMV). This is an industry-wide standardised calculation which tells the company what an HCP would actually earn for their time in practice, based on their specific credentials and qualifications. Chugai uses this information to ensure each HCP's compensation is fair and reasonable for the amount of time necessary to provide the requested service. The fee provided by Chugai is a calculation based on preparation, disturbance (travel) and actual time costs. All arrangements and payments require internal approval which includes review by a compliance officer along with trained staff.</p>
Reporting Date	<p>There is an inevitable delay between the date on which a payment is approved within Chugai and the date on which the payment may be made. Chugai will disclose the details of the payment on the date the payment is processed. This may mean that some projects taking place at the end of one year will be disclosed as part of the next annual reporting period because the payment may not occur until the following year when the invoice has been received and settled. A ToV is paid only after the engagement has taken place.</p>

For how long are ToVs disclosed publicly	The information disclosed remains in the public domain for at least three years from the time of disclosure and archived internally for at least 7 years in keeping with financial archive requirements.
Currency	Where payments were made in a currency other than local, the exchange rate will mean the exact equivalent in sterling will vary according to the date on which the conversion calculation was made. For general purposes, the conversion date should be regarded as the date on which the entry was made in the database. Readers should understand that the amounts disclosed in the local currency could therefore vary slightly from the exact amount paid in the local currency; variations will be greater if there have been significant movements in exchange rate during the reporting period. From 2017 Chugai uses a finance system that gives an automated currency conversion based on the date of payment. For payments made before 2017 Chugai calculated currency conversion based on an average rate over the year.
How we Maintain Accuracy of Beneficiary	<p>Chugai use the OneKey system contracted from IQVIA (https://www.iqvia.com/locations/uk-and-ireland) to provide a comprehensive database on HCPs, HCOs and Patient Organisations. This ensures the highest accuracy of the data and reduces the risk of inaccurate disclosure. Chugai makes great effort to ensure the highest accuracy of data and takes any inaccuracy reported to the company seriously and will strive to resolve immediately. The maximum time for resolution is 28 days.</p> <p>Chugai has a policy to obtain the relevant OneKey ID prior to any work commencing to ensure all ToVs are disclosed accurately.</p>
Sources of Payments	Most disclosed ToVs are made directly by Chugai to an HCP, HCO or Patient Organisation. Disclosed ToVs are also captured where payments are made by other parts of the Chugai Group (described as cross-border payments), R&D related payments made by contracted clinical research organisations (CROs) or external contracted agencies (e.g. travel agents). Chugai UK has an ongoing business partnership with Roche Products Ltd for several co-promotional activities. There are occasions where Roche may undertake activities but where Chugai makes the payment and vice versa. Both companies follow the principle that the company that made the payment is responsible for accurate disclosure and managing consent.
Cross-border Payments	Cross-border payments relate to payments made to an HCP or HCO where the HCP is registered in the UK or Ireland and where there is an organised event and/or where the organising company is based elsewhere. Such engagements are highly regulated at an internal level to be sure arrangements are keeping with regulations in the countries of the engagement, where the HCP is registered to practice and the country where the organising business is based. This includes travel, fees for services, venue, agenda and what materials are available to delegates and speakers, nature and content of the presentation, accommodation and subsistence. The event is also checked against the

	<p>Educational Events and Ethical Evaluation Assessment service (http://www.efpia-e4ethics.eu/usd/e4ethics.nsf).</p> <p>Cross border payments are disclosed in the country where the HCP is registered to practice. For engagements that relate to R&D then these disclosures are presented in aggregated format. For all other forms of engagement, the intention is to always disclose on a named individual basis once the HCP has provided written consent. Where this has not been granted then the payment is disclosed in an aggregated form.</p>
Non-monetary Transfers of Value	Such ToV would be quantified on the cost of the apparatus provided (e.g. as part of a clinical trial) or calculated on an hourly basis determined by the Healthcare Compliance Office on a case by case basis and stated in any agreement.
Multi-year Projects	<p>Chugai will usually engage with an HCP where there is an agreement per engagement. However, there may be occasion where the engagement is ongoing though for the purposes of consent and disclosure a contract will be no longer than that calendar year. Payments will be disclosed in accordance with the year the payment was made.</p> <p>Where projects run for several years Chugai will declare the amount paid relevant to the year in which each part of the payment was made. Thus, a project which spans 2 calendar years and includes several individual ToV during that time will have two associated disclosures; one for each calendar year showing the value of the transfer made in that specific calendar year.</p>
Payments to a Charity	On occasion, an HCP who has provided a service to Chugai may ask for their fee to be paid to charity. Chugai does not allow this, and all payments are preferred to be made directly to the HCP. Instead the HCP is expected to settle tax costs and make any subsequent charitable payment directly of their own volition.
Payments to Healthcare Organisations for Services Provided by Individual HCPs	<p>On occasion, an HCO will insist that any services provided by its HCP employees cannot be contracted with the individual HCP but must be a service contracted through the HCO.</p> <p>Since Chugai is contracting for the services of a named HCP, the fee received by the HCP will be disclosed under that HCP's entry. Any "administration fee" charged by the HCO will be disclosed as a fee for service to that organisation.</p> <p>If the HCP does not receive any additional payment for the service (e.g. because they are speaking at a meeting during normal working hours) then the full amount paid by Chugai will be disclosed against the HCO as a fee for service.</p>
Private Companies and Associated Charities	<p>Where an HCP runs a private company or partnership, charity, etc., for the purposes of their private income, any payments to that organisation will be regarded for disclosure purposes as a payment to the HCP directly.</p> <p>Similarly, organisations where most employees or contracted suppliers are comprised of HCPs, the full value of payments made to such organisations associated with the</p>

	<p>services of a named or identifiable individual will be regarded as if it was a direct payment to the HCP.</p>
<p>Payments to Third Party Organisations for Services Provided by Individual HCPs</p>	<p>Chugai regularly contracts with advertising agencies and PR agencies, etc., for services related to its business. On occasion, the work commissioned by Chugai might be contracted out to an individual HCP. Chugai policy is that all such services must be disclosed to Chugai by the contracted service agency. Chugai will disclose any payments made to the individual HCP by the service agency as if the payment had been made directly by Chugai to that HCP.</p>
<p>Medical Education Grants to Independent Companies</p>	<p>On occasion, Chugai is approached by independent companies to provide funding in relation to medical education projects. The rules related to Chugai's funding in these circumstances require that Chugai has no influence over the details of the project. Chugai would not know whether or which HCPs had been involved in such projects. As such, Chugai does not disclose ToV related to this type of project.</p>
<p>Contributions to Meetings</p>	<p>Chugai will disclose all payments made to medical associations, HCOs, etc. in relation to meetings. This includes direct funding such as sponsorship fees or the right to erect an exhibition stand, costs for staff to attend as delegates and indirect support such as providing a logistics agency or subsidising the cost of registration fees. The details are provided in the relevant line entry.</p> <p>The cost of any sponsorship related directly to food is outside the scope of disclosure unless this is a local code requirement.</p> <p>All costs associated with meetings run solely by Chugai are outside the scope of disclosure except for fees paid to individual HCPs providing services as speakers or travel reimbursement for speakers or delegates. Such payments are disclosed</p>
<p>Sponsorship for HCPs to Attend Medical Meetings</p>	<p>Chugai proudly supports the attendance of HCPs at those medical meetings where there is evidence that the HCP will gain knowledge that will improve or maintain patient care. Chugai will disclose the associated ToV against the individual attendee. Where costs are not individually itemised (e.g. the cost of a bus transferring a group of HCPs from an airport to a conference venue), the total cost will be split equally between all those receiving the benefit.</p> <p>Costs declared include transport, registration fees and accommodation. Costs related to subsistence are not declared but the meal costs are regulated by strict industry guidelines.</p>
<p>Grants to HCOs for Support to Attend Medical Meetings</p>	<p>On occasion, Chugai is asked by an HCO to provide a financial grant to assist its employees to attend medical meetings. Where the payment is associated with named individuals, the disclosure is made as if the money was transferred directly to the named HCP. Where Chugai is not aware of the names of the HCPs receiving the support, the grant is declared against the named HCO.</p>

Donations	<p>A donation is defined as a payment where there is no obligation on the part of the receiver and as such is a free contribution. Such donations cannot be given to an HCP as this would be considered a potential breach of any local anti-bribery laws. Donations can only be provided to HCOs and patient organisations and in these situations there is mandatory requirement for an approved agreement that is signed by both parties on the basis that both parties will publicly disclose the donation. Such donations to HCOs are disclosed on the central portal. Such donations to patient organisations are disclosed on the company website.</p>
Patient Organisations	<p>Patient organisations are providers of essential support and information to those living with medical conditions, as well as their families and carers. Working with these valued organisations allows Chugai to support their efforts with vital resources and is highly regulated. Chugai takes its relationships with Patient organisations very seriously and is committed to ensuring any interaction is justifiable and ethical. For all types of engagements there will be a fully executed contract which is approved internally through a stringent review process. All payments are disclosed on Chugai’s website no later than 30th June for payments made the previous year. Chugai will provide an explanation to the payment and a calculation for this payment as a percentage of the income for the Patient Organisation as a whole.</p> <p>If the money is associated with an individual HCP working with the patient organisation, then the funding will be disclosed twice – the money for the HCP will be disclosed on the ABPI or IPHA disclosure platform against the individual HCP; the overall project will be disclosed on Chugai’s website against the patient organisation entry and will include all payments to patient organisations in the EU.</p>
Joint Working	<p>The Dept of Health defines Joint Working between the NHS and the pharmaceutical industry as situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implantation of patient centered projects and share a commitment to successful delivery. Chugai disclose all payments relating to Joint Working.</p>
Chugai Partners	<p>As an independently listed company Chugai discloses all payments made directly from Chugai bank accounts and listed in the company records as part of its normal business operations.</p> <p>Chugai does not disclose payments made by its shareholders or other stakeholders whether those be individuals or organisations.</p>
Co-marketing Projects	<p>Where Chugai jointly markets a product with another pharmaceutical company, Chugai will only declare those payments made directly from Chugai bank accounts and listed in the company records as part of its normal business operations. ToV made by its co-marketing partners will be disclosed separately by those organisations. This information will be stated on Chugai’s website and a link provided to the business partner.</p>

Distributor Projects	<p>Chugai is a marketing distributor for products where the Market Authorisation Holder is a business partner based in another country. Chugai will only declare those payments made directly from Chugai bank accounts and listed in the company records as part of its normal business operations. ToV made by the Marketing Authorisation Holder will be disclosed separately by those organisations</p>
If the information disclosed is challenged	<p>Chugai takes accurate disclosure seriously. Any challenge to the information disclosed should be made in writing to disclosure@chugai-pharm.co.uk. We will contact you and investigate the matter and amend any information as soon as possible. All necessary changes must be made to the public platform within 28 days, but we will aim to complete this much quicker depending upon the nature and complexity of the information.</p> <p>If you feel the information provided could be presented in a different format, then please contact the company as we welcome the opportunity to improve transparency.</p>
If a member of the public wish for further information	<p>Chugai will provide as much information that is possible within the confines of data privacy and business confidentiality.</p>

How we manage Transfers of Value

Data is collected, recognised and reported using a commercially available database which was customised to Chugai's organisational requirements. This system is used by Chugai to track payments made to all UK HCPs. ToVs are then reconciled against our financial system which identifies and flags relevant vendors.

Payments made to patient organisations will be disclosed separately on the Chugai Pharma UK website (<https://www.chugai-pharm.co.uk/>).

How we manage Consent

Chugai is an ethical pharmaceutical company and we are required to comply with the relevant laws, regulations and applicable industry codes of practice governing our interactions with HCPs and HCOs, including but not limited to The General Data Protection Regulation 2016/679. Chugai is registered with the Information Commissioners Office as a data controller and appointed an external data processor for the purposes for complying with its financial transparency obligations under the APBI Code of Practice.

To legally disclose ToV data on an individual basis Chugai has obtained consent from HCPs except where a local law overrides the interests of secrecy the principles of data protection. Chugai has made every effort to secure and retain a record of the necessary permissions.

Where permission has not been obtained or where the individual HCP has refused permission, Chugai has declared the total spend as an aggregate figure as a separate line entry within the relevant disclosure category.

At the time of disclosure if consent has not been given by a UK HCP, the related ToVs will be included in the Chugai aggregated total.

Chugai allows partial disclosure. A UK HCP may consent to disclosure of sponsorship payments and decline to consent consultant payments. In this case the sponsorship ToVs would be disclosed on an individual basis and the consultancy ToVs will be disclosed in the aggregate (non-identifiable format).

Chugai fully supports the concepts of transparency and privacy. Information disclosed must remain in the public domain for at least three years from the time of disclosure and Chugai will document all disclosures and retain the records for at least five years after the end of the calendar year to which they relate. Situations can be challenging for disclosure, but Chugai is committed to maintaining full transparency and balance data privacy wishes and sensitivities. Examples are as following but not limited to:

- If an HCP chooses to withdraw consent for an engagement at any time, Chugai has decided that the company will not change its relationship with the HCP in those circumstances where consent is not given or subsequently withdrawn in the spirit that consent should be freely given. This will not be the case in those countries where local laws supersede data protection rights.

- In the situation where an HCP received a payment from Chugai and subsequently dies and this information is known to the company then the payment is not disclosed or is removed.
- In the situation where an HCP retires from clinical practice and no longer maintains a membership to a body regulating practice then the payment will be disclosed except where IQVIA remove the HCP from the OneKey database when the payment is then removed.
- In the situation where an HCP receives a payment and provides consent for disclosure but then subsequently changes their name (e.g. following marriage) then if Chugai is made aware of this change then will amend the payment details to the new name if available in the OneKey database.

How we manage Research and Development

All payments to an HCP, HCO and patient organisations relating to research and development are disclosed as aggregate figures in accordance with local Codes of Practice.

Items included:

- Pre-clinical research and clinical research (includes Investigator Sponsored Research (ISR))
- Non-interventional Studies
- Advisory Boards and consultancy services in relation to clinical research
- Real world data studies and Health Outcomes research
- Fees for service to HCPs, ORDMS and HCOs in relation to study sites (including where these fees have been made by CRO on behalf of Roche
- Travel and accommodation in relation to a fee for service contract
- Items not included
- Overhead cost (including CRO fees)
- Materials (such as study medication/injections/kits)

It is common practice for a pharmaceutical company to engage a clinical research organisation (CRO) to manage specific research projects and clinical trials. In these circumstances the CRO may make payments to HCPs and HCOs on behalf of Chugai. Such indirect payments are captured on a quarterly basis and provided to Chugai or processed through a business partner, Roche and subsequently disclosed by Chugai.

Tax and VAT considerations

It is the responsibility of the receiving HCP to settle local tax requirements. The contract for each engagement should be agreed and signed by both parties prior to any work being undertaken and there is a clear statement regarding tax payment responsibilities. Where a payment has been made to an HCO or third-party vendor then where VAT has been included this has been settled by Chugai and where this has occurred this has been highlighted in the disclosure per line. There are occasions where VAT is added as part of an invoice but was not stated in the fully executed Agreement. Chugai may need to settle VAT as a separate and subsequent payment and in that situation, Chugai will manually add the VAT costs to the information disclosed.

Link to ABPI Code

<http://www.pmcpa.org.uk/thecode/InteractiveCode2016/Pages/default.aspx>

Link to ABPI Disclosure Portal

<http://www.abpi.org.uk/our-work/disclosure/Pages/DocumentLibrary.aspx>

Link to IPHA Code and Supporting Documents

<http://www.ipha.ie/alist/publications.aspx?article=f8f9c1e9-344a-468c-b7d2-dc83530513b1>

Link to IPHA Disclosure Portal

<https://www.transferofvalue.ie/>

Link to EFPIA Code

<https://www.efpia.eu/relationships-codes/disclosure-of-payments-to-hcps/>

Contacts

Chugai welcomes the opportunity to discuss the principles of transparency and can be contacted in the email below. However, Chugai is unable to discuss detail relating to specific payments.

Healthcare Compliance Team

Chugai Pharma Europe

For further information, please contact:

disclosure@chugai-pharm.co.uk

+44 208 9875680